Project Detail
"MK8259-022: An open label, single group assignment design study to correlate soluble ST2 with clinical, endoscopic and histological activity in moderate to severe Ulcerative Colitis patients under golimumab (Evolution)"
 
Team
 
Sponsor
Merck
 
Dates and Lifetime
From: 2015-02-05 To: 2020-02-05
Duration: 60 months
 
Reference
MK8259-022
  
Send Email
From
To
Subject